| Literature DB >> 17190952 |
J Jankovic1, C Hunter, B Z Dolimbek, G S Dolimbek, C H Adler, A Brashear, C L Comella, M Gordon, D E Riley, K Sethi, C Singer, M Stacy, D Tarsy, M Z Atassi.
Abstract
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17190952 DOI： 10.1212/01.wnl.0000249308.66959.43
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910